Significant Development in the Diagnosis of Brain Tumors: Cerebrospinal Fluid Test CSF-BAM
In this article
⚗️ CSF-BAM: A Multi-Analyte CSF Test for Brain Tumor Diagnosis
Brain biopsy remains the invasive gold standard and may be risky or unfeasible in deep or eloquent areas. CSF-BAM analyzes a small cerebrospinal fluid sample and combines multiple biomarkers in one assay to support faster, safer decision-making.
📊 Study Design
Two cohorts were evaluated. The validation set included 206 CSF samples from patients with high-grade glioma, medulloblastoma, brain metastases, and CNS lymphoma. An additional 129 CSF samples focused on the most common aggressive tumor types.
The assay integrates BCR/TCR repertoire, chromosomal aneuploidy, and tumor-specific mutations in a single multi-analyte test using dual-strand DNA amplification.
📖 Publication:
Research Brief · August 25, 2025
Detection of human brain cancers using genomic and immune cell characterization of cerebrospinal fluid through CSF-BAM
Authors include Alexander H. Pearlman, Yuxuan Wang, Anita Kalluri, Joshua D. Cohen, Bert Vogelstein, Christopher Douville, Chetan Bettegowda, and others
🔗 Cancer Discovery · DOI: 10.1158/2159-8290.CD-24-1788
🚀 Key Findings
PPV/NPV are not reported in this study and are therefore not displayed here. This panel shows only the reported sensitivity and specificity.
🧬 Analytes & Rationale
- BCR/TCR repertoire: reflects adaptive immune response in CSF; clonal expansions may indicate tumor-related immunity.
- Aneuploidy: copy-number gains/losses capture large-scale genomic instability common in cancers.
- Tumor mutations: driver/characteristic variants support tumor origin and classification.
- Integrated readout: combining markers reduces false positives and improves confidence in equivocal cases.
🧭 Patient Journey (Example)
Suspicion
Neurologic symptoms + lesion on imaging
CSF Sampling
Indication & safety assessment
CSF-BAM
BCR/TCR · aneuploidy · mutation panel
Decision
Biopsy need, follow-up or treatment plan
⚖️ Risk–Benefit Matrix & Decision Flow
Low Risk · High Benefit
Positive CSF-BAM; prioritize biopsy planning
High Risk · High Benefit
Very low false-positive rate supports action in risky biopsy candidates
Low Risk · Limited Benefit
Negative test; if clinical suspicion is low, consider surveillance
High Risk · Limited Benefit
Negative test but high suspicion → advanced imaging/alternative biomarkers
⚠️ Limitations
- Selected cohorts → needs larger, multi-center real-world validation for generalizability.
- Negative result ≠ absolute exclusion; pursue work-up if clinical suspicion remains high.
- Pre-analytical variables (collection, handling, cellular contamination) may impact performance.
👨⚕️ Our Take
CSF-BAM provides a dual view by reading tumor DNA signals and the immune repertoire in one assay. The reported 100% specificity implies an extremely low false-positive risk, enabling more selective biopsy decisions. With 81% sensitivity, negative results should still be interpreted in clinical context.
📝 Conclusion
- CSF-BAM shows 81% sensitivity and 100% specificity across studied cohorts.
- Integrated, multi-analyte readout can reduce diagnostic uncertainty in challenging cases.
- Broader validation may position it as a safer, faster aid that could reduce biopsy need.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.